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Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated
with ribosomal gene mutations that lead to ribosomal insufficiency. DBA is characterized by
anemia, congenital anomalies, and cancer predisposition. Treatment for DBA is associated
with significant morbidity. Here, we report the identification of Nemo-like kinase (NLK) as a
potential target for DBA therapy. To identify new DBA targets, we screen for small molecules
that increase erythroid expansion in mouse models of DBA. This screen identified a com-
pound that inhibits NLK. Chemical and genetic inhibition of NLK increases erythroid expan-
sion in mouse and human progenitors, including bone marrow cells from DBA patients. In
DBA models and patient samples, aberrant NLK activation is initiated at the Megakaryocyte/
Erythroid Progenitor (MEP) stage of differentiation and is not observed in non-erythroid
hematopoietic lineages or healthy erythroblasts. We propose that NLK mediates aberrant
erythropoiesis in DBA and is a potential target for therapy.
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D iamond Blackfan Anemia (DBA) is a congenital bonemarrow failure syndrome usually diagnosed within thefirst year of life1. Treatment for DBA, including chronic
transfusions, steroid therapy, and stem cell transplantation, are
associated with significant morbidity. Therefore, new therapies
are needed to treat DBA patients.
Approximately 70% of DBA patients possess a mutation in one
of 19 genes that encode ribosomal proteins, with mutations in
Ribosomal Protein S19 (RPS19) accounting for over 25% and
RPL11 comprising ~5% of cases. Complete loss of ribosomal
components is embryonic lethal, while mutations resulting in
haploinsufficiency cause erythropoiesis failure due to a block in
differentiation of early erythroid progenitors2.
The master hematopoietic transcription factor c-Myb is
expressed in hematopoietic stem cells and early progenitors and is
upregulated during early erythropoiesis. Myb serves a number of
cellular roles in erythropoiesis, including transcriptional regula-
tion of the master regulators KLF1 and LMO23,4 and has been
reported to be downregulated in RPS19-insufficiency5.
NLK is an atypical member of the MAP kinase family and
contributes to morphological changes during early embryogen-
esis, nervous system development and has also been implicated in
the pathogenesis of several cancers6–12. NLK regulates a diverse
array of signaling pathways6. In Wnt-stimulated HEK293T cells,
NLK phosphorylates c-Myb, priming it for ubiquitination by the
E3-ubiquitin kinase Fbxw7 and subsequent proteasome degra-
dation13–15. Raptor is another substrate of NLK preventing
mTOR-associated Raptor from localizing to the lysosomal
membrane for activation16. Additional NLK substrates regulated
by NLK phosphorylation include STAT317, ATF518, FoxO119,
Lef120, and HDAC21.
NLK expression is tissue specific and is regulated by micro-
RNAs (miRNAs), including miR20822 and miR1816,23,24. Family
members of miR181 are reported to control NLK expression in a
variety of tissues6.
Here we report NLK activity is increased in erythroid pro-
genitors from DBA models, and suppression of NLK activity
increases erythroid expansion. Our results suggest that NLK is
critical to the pathogenesis of DBA and is a potential target for
therapy.
Results
Identification of small molecules that rescue erythropoiesis.
Approximately 12,000 compounds from the Chemical Biology
Consortium, Sweden (CBCS), Stockholm and Chemical Biology
and Therapeutics (CBT), Lund were screened for the ability to
rescue c-Kit+ erythroid expansion in RPS19-insufficient Lin-Kit+
progenitors from mouse embryonic (E14.5–E15.5) fetal livers over
4 days25 (Fig. 1a). Compound SB431542, a known inhibitor of the
TGFβ pathway was among the strongest hits. This compound was
also identified as a hit in a similar screen for rescued proliferation of
reprogrammed hematopoietic progenitors from DBA patients26.
We sought to determine if SB431542 rescued proliferation in our
screen through inhibition of TGFβ or an off-target effect. Eight
TGFβ inhibitors in the murine RPS19-insufficient model were
tested at 10 µM and only SB431542 and SD208 significantly rescued
c-Kit+ erythroid expansion (p= 0.0014, paired Studentʼs t test),
while six other TGFβ inhibitors displayed no significant effect
(Fig. 1b). Erythroid growth in murine RPS19-insufficient cells
improved with SB431542 and SD208 with EC50s of 5 µM and
0.7 µM respectively (Supplementary Fig. 1a). All of the compounds
inhibited TGFβ in these cells as each rescued the growth suppres-
sion of TGFβ–treated c-Kit+ cells (Fig. 1c).
To determine if SD208 and SB431542 increases erythropoiesis
in human DBA models, human cord blood (CB)-derived CD34+
hematopoietic stem and progenitor cells (HSPCs) were trans-
duced with GFP co-expressed with shRNA against control
(luciferase) or RPS19 and treated with a more extensive panel
of TGFβR1 inhibitors, including SD208 and SB431542. In vitro
differentiation of GFP+RPS19-insufficient HSPCs demonstrated
impaired hematopoiesis. As in DBA, erythroid differentiation was
most dramatically impacted (80–90%) while CD41+ megakar-
yocyte and CD11b+ myeloid lineages display 20–35% reduc-
tions27–30. The two compounds (SD208 and SB431542) that
increased erythroid expansion in murine RPS19-insufficient
progenitors also increased human erythroid progenitor expan-
sion. Galunisertib was not tested in the murine model but also
significantly increased erythropoiesis in human DBA models.
Compared with control treated cells, SD208, SB431542, and
Galunisertib increased erythropoiesis in RPS19-insufficiency by
6.3-fold, 3.2-fold and 3.2-fold, respectively (Fig. 1d). No
significant effect was observed in CD41+ megakaryocyte or
CD11b+ myeloid populations treated with these compounds
(Supplementary Fig. 1b).
Our results demonstrate that the effect of SD208 and SB431542
was not through TGFβ inhibition in mouse progenitors (Fig. 1b,
c), however, differences between humans and mice have been
reported31–33. Since TGFβ inhibits human erythroid and myeloid
development34,35, we compared the ability of SD208 (improved
erythropoiesis) and SB525334 (no impact on erythropoiesis) to
rescue TGFβ-mediated growth suppression. The presence of
either SD208 or SB525334 restored ribosome-competent ery-
throid (Fig. 1e.i) and myeloid expansion (Fig.1e.iii) of TGFβ-
treated cells comparable to untreated controls.
In RPS19-insufficient cells, SD208 increased erythroid expan-
sion by 428.6% of vehicle treated control cells. This increase was
not due to TGFβ inhibition, as it was observed in cells treated
with or without TGFβ (Fig. 1e.iii). SB525334 restored erythropoi-
esis to 128.6% of controls in TGFβ-treated cells but did not
influence cells that were not treated with TGFβ (Fig. 1e.iii). Both
inhibitors equally rescued expansion of TGFβ-treated RPS19-
insufficient myeloid cells (Fig. 1e.iv). This indicates that improved
erythropoiesis observed by SD208 treatment is not due to TGFβ
inhibition in human models of DBA.
To determine if SD208, SB431542 and Galunisertib directly
inhibit NLK, all 12 TGFβ inhibitors were added to activated NLK
and TGFβR1 and in vitro kinase activity was assessed (see
Supplementary Fig. 1c). Similar to functional assays (Fig. 1c, e),
all the TGFβR1 inhibitors tested suppressed the phosphorylation
of TGFβR1 substrates, Smad2 and Smad3 (Supplementary Fig. 1c)
at 1 µM, ranging from ~50 to 90% efficiency. In contrast, the
three compounds that increased erythroid expansion in RPS19-
insufficiency (SD208, SB431542, and Galunisertib) inhibited
NLK-mediated phosphorylation of NLK substrates NLK, c-Myb
and Raptor by ~80%, 55% and 40–45%, respectively (Supple-
mentary Fig. 1c).
Immunopurified NLK from drug-treated cells demonstrated
the same activity profile as active NLK that had been treated with
the drug panel in vitro (Supplementary Fig. 1d). Analysis of
SD208, SB431542, and Galunisertib revealed IC50 values of 50.6,
87.5, and 62.3 nM against TGFβR1 and IC50 values of 435 nM,
1.07 µM and 1.34 µM against NLK (Supplementary Fig. 1e).
SD208, SB431542, and Galunisertib are reported to inhibit
TGFβR1 with IC50 values of 4935, 9436, and 69 nM37 and Eli
Lilly has reported NLK inhibition with an IC50 value of 0.91 µM
for Galunisertib38.
NLK is target of SD208 in ribosomal insufficiency. Kinase
Profiling of SD208 indicated a number of kinases are strongly
inhibited by this compound (Supplementary Fig. 2a). Many of the
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kinases were not studied because compounds that specifically
target them did not improve erythropoiesis in our screen. How-
ever, SD208 inhibited p38 and NLK kinase activity by 99.6% and
96.8%, respectively at 10 µM (Supplementary Fig. 2a) and the
low-specificity p38 inhibitor SB203580 improves erythropoiesis in
RPS19-insufficient HSPCs27. Interestingly, SB203580 also inhibits
NLK at similar concentrations39–41. We compared SD208 with
SB203580 in addition to two other p38 inhibitors that do not
target NLK41,42 (PH797804 and SCIO-469) and only SD208 and
SB203580 improved erythropoiesis, indicating suppression of p38
does not improve erythropoiesis. All four inhibitors potently
reduced p38 phosphorylation (Supplementary Fig. 2b).
To determine if NLK contributes to decreased erythropoiesis in






































































































































































































































































































































































Fig. 1 TGFβR1 inhibitors that improve erythropoiesis also inhibit NLK activity. a Schematic of assay utilized to screen compounds for effects on erythroid
progenitor cell expansion. Lin-Kit+ fetal liver cells were obtained from mouse embryos expressing tet-on shRNA against RPS19, at day E14.5-15.5. Cells
were plated at 2000 cell per well in 96-well plates in the presence or absence of doxycycline. Relative amounts of live cells were quantified by luciferase-
based Cell titer-Glo® assay. b TGFβR1 inhibitors were assessed for their ability to increase cell expansion in RPS19-insuffiency. As a control, vehicle alone
(no doxycycline) is represented at the far left while all other samples were treated with doxycycline to induce RPS19-insufficiency. c Kit+ erythroid
progenitors were grown in the absence of doxycycline and in the presence of 10 µM of indicated compound. In addition, cells were treated with 5 ng/ml of
TGFβ1 for 5 days before being subjected to Cell titer-Glo® assay. d Differentiating cord blood CD34+ progenitors were transduced with shRNA against
luciferase or RPS19 and treated with inhibitors at working concentrations for TGFβ inhibition every three days. Cells were counted and CD235+ erythroid
cells were assessed by flow cytometry after 15 days. e Cord Blood CD34+ progenitors were transduced with shRNA against luciferase (i and ii) or RPS19 (iii
and iv) differentiated in erythroid media for 15 days alone, or the indicated combinations of 5 ng/ml TGFβ1, SB525334 or SD208 at 5 µM. Cells were
counted and CD235+ erythroid (i and iii) and CD11b+ myeloid cell (ii and iv) percentages were determined by flow cytometry. The number of erythroid or
myeloid cells is expressed as a percentage of the number of that lineage with no cytokine or drug treatment. Bars represent means ± SD with individual data
points overlaid. n= 3 independent experiments performed in triplicate. Statistics: two-tailed Student’s t test, significant *p < 0.05. Also see Supplementary
Fig. 1. Erythroid expansion is depicted in red while myeloid is in purple. Source data are provided as a Source Data file.
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against RPS19 in cord blood (CB) CD34+ HSPCs and
differentiated them in erythroid-promoting media. RPS19-
insufficiency reduced maturing CD235+ erythroblast expansion
to 21.2% of controls and silencing NLK improved it to 46.7%
(p= 0.0216) of ribosome-competent controls (Fig. 2a.i). Non-
erythroid myelopoiesis was mildly reduced by RPS19-
insufficiency but NLK suppression had a negligible impact (p=
0.8296). Likewise, NLK suppression did not affect erythropoiesis
or myelopoiesis in ribosome-competent controls (p= 0.2749 and
0.9438) (Fig. 2a.ii, iii).
We re-introduced recombinant NLK (including 3′UTR)
engineered with a nucleotide sequence unable to be recognized
by the siRNA, as well as using a series of shRNAs against different
regions of NLK, to rule out the possibility of off-target effects of
NLK siRNA leading to improved erythropoiesis (Supplementary
Fig. 2c).
While liquid culture allows us to quantify both immature and
mature cell populations, we also assessed the role of NLK in
colony assays. Erythroid BFU-E colonies decreased to 18.8% of
controls in RPS19-insufficient progenitors. Expression of siRNA
against NLK did not affect BFU-E colony numbers in ribosome-
competent progenitors (p= 0.4134). However, we observed a 2.9-
fold increase in erythroid (BFU-E) colonies from 18.8 to 53.6%
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Fig. 2 NLK expression contributes to erythroid defects in RPS19-insufficiency. a Cord blood CD34+ progenitors were transduced with lentivirus
expressing shRNA against luciferase (shLuc) or RPS19 (shRPS19) co-expressing GFP, along with siRNA targeting NLK (siNLK) co-expressing RFP and a
siNLK-resistant NLK (NLKesc) co-expressing puromycin resistance. GFP+RFP+ progenitors were differentiated in erythroid media for 15 days prior to
counting and assessment for surface expression of (i) CD235 (erythroid), (ii) CD41a (megakaryocyte) and (iii) CD11b (myeloid) cellular markers by flow
cytometry. Within each sample, the total number of cells was multiplied by the percentage of cells expressing each differentiation marker and values were
normalized and expressed as a percentage of control (shLuc/NT). b Transduced GFP+,RFP+ cord blood CD34+ progenitors were differentiated in
methylcellulose for 12–15 days and colonies were scored as either erythroid (i) or myeloid (ii). c Expression of NLK, RPS19, and GAPDH were analyzed by
Western blot analysis after 5 days of differentiation. d CD34+ progenitors were transduced with shRNA against luciferase or RPS19 and non-targeting or
siRNA against NLK. After sorting, samples were split into two groups and either treated with vehicle or SD208 every three days. After 15 days cells were
counted and subject to flow cytometry to compare the expansion of maturing CD235+ erythroid (i) and CD11b+ myeloid cells (ii). Bars represent means ±
SD with individual data points overlaid. n= 3 independent experiments performed in triplicate. Statistics: two-tailed Student’s t test, significant *p < 0.05.
Also see Supplementary Fig. 2. Erythroid expansion is depicted in red, megakaryocyte in blue and myeloid in purple. Source data are provided as a Source
Data file.
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(Fig. 2b.i). NLK siRNA did not affect myeloid CFU-GM colonies
(p= 0.8141) (Fig. 2b.ii). NLK expression was reduced 80–90%
upon expression of siRNA (Fig. 2c). p values were defined by
paired Studentʼs t test.
NLK shares a number of conserved regions with cyclin
dependent kinases (cdks)6,43. The siRNA against NLK was
designed not to target other conserved genes, however we
examined the impact of the siRNA on expression of kinases with
similar substrate profiles by Western blot analysis. No reduction
of TAK1, p38, JNK, ERK1/2, Cdk1, or Cdk2 protein was observed
upon expression of siRNA against NLK. Mild reductions in p38
(16%), JNK (7%), and ERK1/2 (14%) phosphorylation were
observed (Supplementary Fig. 2d).
As observed previously (Figs. 1d, 2a), SD208 treatment alone
improved RPS19-insufficient CD235+ erythroblast expansion
from 4.9% to 40.3% observed in controls, while siRNA against
NLK improved erythropoiesis from 4.9% to 34.2% compared with
ribosome-competent controls (Fig. 2d.i). SD208 treatment in
RPS19-insufficient erythroid progenitors expressing siRNA
against NLK failed to show significant improvement in erythroid
expansion over either treatment alone (compare increases
from 4.9% to 40.3%, 34.2% and 43.6% for SD208, siNLK and
combined, respectively—p= 0.4633 and 0.1825, paired Studentʼs
t test.) (Fig. 2d.i), suggesting the most relevant target of this
compound in ribosomal insufficiency is NLK. No NLK effect was
observed in myeloid expansion (Fig. 2d.ii).
Effect is not through modulation of NLK expression. Using
three different NLK antibodies, we analyzed NLK protein
expression by Western blot analysis in CD34+, CD71+ and
CD71− populations (Fig. 3a). CD71 is highly expressed in
erythroid progenitors but at lower levels in megakaryocyte and
Megakaryocyte/Erythroid Progenitor (MEP) populations44. We
did not observe differences in NLK expression between control
and RPS19-insufficiency in CD71+ or CD71− populations
(Fig. 3a). However, NLK expression was significantly reduced in
the CD71− population relative to the CD71+ and CD34+ HSPC
population, suggesting that NLK expression is reduced as cells
differentiate along the non-erythroid lineage (Fig. 3a). RPS19-
insufficiency did not impact NLK mRNA expression in any
lineage, but was much higher in erythroid populations (Fig. 3b).
NLK Activity is increased in RPS-19 insufficient cells. NLK has
been reported to phosphorylate a number of substrates, including
c-Myb4,13–15,45 and Raptor16. Activated NLK is phosphorylated
on Thr2986,46, so we analyzed the phosphorylation status of
NLK from control and RPS19-insufficient CD71+ erythroid and
CD71− non-erythroid populations after 10 days of differentiation
using a phospho-specific antibody by Western blot analysis. In
CD71+ erythroblasts, RPS19-insufficiency increased phosphor-
ylation of NLK at Thr298 2.5-fold of controls (Fig. 3c).
NLK dimerizes upon activation46. Corresponding with
increased phosphorylation of NLK at Thr298, we observed a
3.9-fold (p= 0.0124) increase in dimerization of transduced YFP-
and CFP-tagged NLK (as measured by fluorescence resonance
energy transfer) in populations expressing shRNA against RPS19
relative to controls (Fig. 3d).
To test NLK activity in small populations of cells, we designed
a highly sensitive in vitro kinase assay examining the ability of
immunopurified NLK to phosphorylate three known NLK
substrates; NLK, c-Myb, and Raptor (see Supplementary Fig. 3a).
Corresponding with pThr298-NLK phosphorylation and NLK
dimerization, in vitro NLK activity was robustly induced (Fig. 3e.
i–iii left panels). CD235+, CD41a+, and CD11b+ are markers
of maturing erythroblasts, megakaryocytes, and myeloid
populations respectively, and elevated NLK activity was observed
in RPS19-insufficient CD235+ erythroblasts but not CD41+ or
CD11b+ populations (Fig. 3e.i–iii right panels). Compared with
controls, immunoprecipitated NLK from RPS19-insufficient
CD71+ and CD235+ erythroid populations, increased NLK
phosphorylation by 2.7- and 3.4-fold (p= 0.011 and 0.0025);
c-Myb phosphorylation increased by 3.9- and 4.7-fold (p=
0.0268 and 0.0175); and Raptor phosphorylation increased by 6.1-
and 7.3-fold (p= 0.0433 and 0.032), respectively. No significant
increase in phosphorylation was detected in other hematopoietic
lineages (Fig. 3e) and p values were defined by paired Studentʼs
t test. The assay was validated in Kp53A1 myeloid leukemia cells
(Supplementary Fig. 3b–d) and specificity of the NLK antibody
was also confirmed (Supplementary Fig. 3b, e, f).
We did not see an association of p38 with immunoprecipitated
NLK (Supplementary Fig. 3e) however, as an association between
the two proteins has been reported17 we examined this in greater
detail. As observed by Ohnishi et al.17, endogenous p38 could not
be detected with immunoprecipitated NLK but NLK could be
detected with immunoprecipitated p38 (Supplementary Fig. 4a).
This suggests the NLK epitope may be masked by p38 binding
and prevent the complex being immunoprecipitated with an NLK
antibody, and therefore exclude NLK-associated p38 from our
kinase assay.
But as p38 can phosphorylate NLK, Myb and Raptor in vitro,
we performed a series of experiments that indicate NLK-
associated p38 is not contributing to substrate phosphorylation.
We determined the IC50 values of a panel of eight p38 inhibitors
against p38 and NLK in our in vitro kinase assays. For
comparison, reported IC50 values from bioassay results submitted
to the National Center for Biotechnology Information PubChem
Database were tabulated. No compound inhibited NLK with the
same specificity as p38. Moreover, for each inhibitor with a
reported IC50 for NLK, our observed NLK IC50 was similar to the
reported NLK IC50 and differed significantly from that of p38
(Fig. 3f).
The IC50 values we obtained for NLK differ from reported
values for p38. SD208, SB431542, and Galunisertib inhibit NLK
with IC50 values of 435 nM, 1.07 µM and 1.34 µM but are
reported to inhibit p38 with IC50 values of 850 nM, 9 µM and
405 nM, respectively. We observed SD208 inhibited p38 with an
IC50 value of 910 nM (Supplementary Fig. 4b). This data support
our conclusion that these compounds increase erythropoiesis in
ribosome insufficiency through the inhibition of NLK and not
p38. As it was reported that p38 is required for NLK function in
anterior development in Xenopus17, our data suggest the role for
p38 in NLK activation is context-dependent. As p38 phosphor-
ylates NLK at a specific serine residue, it is possible redundancy
exists between kinases that can phosphorylate this residue under
different conditions.
We found no evidence of NLK-associated p38 contributing to
the effects of RPS19-insufficiency, however other NLK-associated
kinases could not be ruled out. Therefore, in the context of NLK
knockdown with siRNA, we re-expressed siRNA-resistant wild-
type (WT) or kinase-deficient NLK. No kinase activity was
detected after immunoprecipitation of the kinase-deficient
mutant, indicating no associated kinases were present (Supple-
mentary Fig. 4c).
NLK is activated in murine and human models and DBA
patients. Along with RPS19, RPL11 is one of the most com-
monly mutated genes in DBA1. Transduction of CD34+ cells
isolated from human cord blood with lentivirus expressing
shRNA sequences selected for approximately 50% knockdown
efficiency against RPS19 or RPL11 recapitulate erythropoiesis
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17100-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3344 | https://doi.org/10.1038/s41467-020-17100-z | www.nature.com/naturecommunications 5
defects of DBA when differentiated in vitro27. CB CD34+ cells
were transduced with lentivirus expressing GFP and shRNA
against RPS19, RPL11, or control (luciferase). Cells were col-
lected each day and assayed for NLK activity against NLK (i),
c-Myb (ii), and Raptor (iii) and expression of NLK (iv), and
RPS19 or RPL11 (v). We observed a mild increase in in vitro
phosphorylation of all three substrates at day 3 in control cells
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Fig. 3 NLK expression is higher in erythroid progenitors and is activated in RPS19-insufficiency. a Transduced CD34+ CB HSPCs were differentiated for
10 days and CD71+ and CD71– fractions were probed by Western blot analysis for NLK using three different NLK antibodies. Equivalent protein was loaded
between samples. b—blue Transduced progenitors were differentiated for 15 days and sorted for surface expression of CD235+ , CD41+ and CD11b+
population NLK mRNA was assessed by qRT-PCR. c Control and shRPS19-transduced CB progenitors were differentiated for 10 days prior to separation
into CD71+ and CD71- populations and assessed for pThr298-NLK phosphorylation by Western blot analysis. d—purple CB CD34+ progenitors were
transduced with shRNA against luciferase (shLuc) or RPS19 (shRPS19) along with CFP-NLK and YFP-NLK and differentiated for 10 days. NLK dimerization
was quantified by FRET. e—left panel NLK was immunoprecipitated from transduced differentiating CD71+ and CD71- populations after 10 days, and
incubated in the presence of ATP, Mg2+ and dephosphorylated NLK (i orange), c-Myb (ii—blue) and Raptor (iii—green) for 30min at 37 °C.
Phosphorylation was detected by a combination of anti-phosphoserine-HRP and anti-phosphothreonine-HRP antibodies, or mouse anti-phosphoserine and
anti-mouse-HRP antibodies. e—right panel For comparison, NLK in vitro kinase activity was assessed from CD235+, CD41+ and CD11b+ populations
enriched after identical treatments. f A panel of eight small molecule p38 inhibitors were titrated into in vitro kinase assays in the presence of activated
NLK or p38 from stimulated Kp53A1 cells. The IC50 for NLK and p38 for each compound was calculated. The data are represented diagrammatically with
IC50 values represented as vertical lines along a concentration gradient for NLK and p38. Kinase activity is represented as blue and the extent of inhibition
is depicted in white. Our observed values (shown in orange) can be easily compared with documented IC50 values (shown in black) for each compound
against each kinase. Bars represent means ± SD with individual data points overlaid. n= 3 independent experiments performed in triplicate.Statistics: two-
tailed Student’s t test, significant *p < 0.05. Also see Supplementary Figs. 3 and 4. Source data are provided as a Source Data file.
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control HSPCs during early differentiation. In contrast, a dra-
matic and sustained increase in NLK activity was induced in
RPS19-insufficient cells with NLK, Myb, and Raptor phos-
phorylation exceeding controls by four-, six-, and nine-fold,
respectively (Fig. 4a.i–iii left panels). Activation of NLK in
RPL11-insufficiency paralleled RPS19-insufficiency, but was
less robust (Fig. 4a.i–iii right panels). It should be noted that
NLK activity is being assessed from the entire population of
differentiating progenitors (erythroid and non-erythroid com-
bined) so the observed reduction in NLK expression likely
reflects a reduced ratio of high NLK-expressing erythroid
progenitors relative to low NLK-expressing non-erythroid
progenitors in ribosome-insufficiency (Fig. 4a.v). Sorting of
populations into CD71+ and CD71− populations confirmed no
difference in NLK expression between control and RPS19-
insufficiency within populations (Fig. 3a, b).
Subtle differences in erythroid development have been reported
between various sources of CD34+ progenitors47. We observed
low basal NLK activity in differentiating progenitors derived from
healthy control cord blood, fetal liver, and peripheral blood, with
significant upregulation of NLK activity in all three progenitor
sources during RPS19-insufficiency (Supplementary Fig. 5a).
Despite differences between human and murine hematopoi-


















































































































































































































































































































































Fig. 4 NLK is activated in erythroid progenitors from human and murine models of DBA and DBA patient bone marrow. a Cord blood CD34+
progenitors were transduced with lentivirus co-expressing shRNA against luciferase (shLuc), RPS19 (shRPS19) or RPL11 (shRPL11) and GFP. After 36 h
GFP+ cells were differentiated in erythroid media for the indicated days prior to immunopurifying NLK for kinase assay measuring in vitro phosphorylation
of NLK (i—orange), c-Myb (ii—blue) and Raptor (iii—green) and assessment of RPS19/RPL11 (iv—gray), and NLK (v—blue) expression by qRT-PCR. Solid
circles indicate shLuc while open circles indicate shRPS19 or shRPL11. b Lin-Kit+ hematopoietic progenitors were obtained from mouse embryos expressing
tetracycline-inducible shRNA against RPS19, at day E14.5. Cells were grown in the presence or absence of doxycycline for 8 days and subjected to
NLK kinase assay qRT-PCR for expression of murine RPS19 and NLK (b-left). Lin-Kit+ progenitors were purified from bone marrow of 3 RPL11+/+ and
3 RPL11+/lox tamoxifen-treated mice and analyzed for NLK activity by kinase assay, as well as NLK and RPL11 expression by qRT-PCR (b-right). c NLK was
immunopurified from 5000 bone marrow mononuclear cells derived from bone marrow aspirates of healthy control and three DBA patients carrying RPS19
mutations. Bars represent means ± SD with individual data points overlaid. n= 3 independent experiments performed in triplicate. Statistics: two-tailed
Student’s t test, significant *p < 0.05.Also see Supplementary Fig. 5. Source data are provided as a Source Data file.
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RPL11 insufficiency49,50. We expanded hematopoietic progenitor
Lin-Kit+ mouse fetal (E14.5) liver cells expressing a tetracycline-
inducible shRNA against RPS19. NLK immunoprecipitated from
doxycycline-treated cells demonstrated significantly increased
activity (1.9-, 3.2-, and 5.3-fold above controls for NLK (i), c-Myb
(ii), and Raptor respectively (iii)), (Fig. 4b—left panels).
Similarly, mice expressing a single copy of the RPL11 allele
develop anemia50. Mice heterozygous for RPL11flox were treated
with tamoxifen for 8 weeks and Lin-Kit+ hematopoietic
progenitors were isolated and NLK activity was increased in all
three RPL11-haploinsufficient mice (2.1-, 4.1- and 7.2-fold for
NLK (i), c-Myb (ii), and Raptor (iii), respectively) compared with
tamoxifen-treated wild type mice (Fig. 4b—right panels).
Collectively, these data indicate that NLK is activated in HPSCs
from murine models of DBA.
NLK activity was also higher in DBA patient cells than healthy
controls. NLK immunopurified from mononuclear cells from the
bone marrow aspirates of three DBA patients carrying different
RPS19 mutations significantly increased phosphorylation of all
three substrates compared with healthy control cells (2.2-, 2.0-,
and 2.2-fold NLK phosphorylation (i), 3.3-, 2.4-, and 2.6-fold c-
Myb phosphorylation (ii), and 4.8-, 4.1-, and 4.2-fold Raptor
phosphorylation (iii)). As expected, reduced NLK expression was
observed in bone marrow mononuclear cells from 3 DBA patient
samples, reflecting the increased ratio of low NLK-expressing
non-erythroid progenitors in the heterogeneous population
(Fig. 4c.iv). RPS19 expression was significantly lower in bone
marrow cells from DBA patients (0.6, 0.8 and 0.6-fold) compared
with control cells (Fig. 4c.v).
Induced-pluripotent stem cells (iPSCs) generated from a DBA
patient carrying a mutation in RPS26 (C74A) robustly induced
NLK activity. Activation was initiated during early differentiation
and was sustained throughout the 10-day time course. Expression
of a tetracycline-inducible WT RPS26 significantly reduced NLK
activity (Supplementary Fig. 5b). Western blot analysis confirmed
a 1.95 fold increase (p= 0.0261, paired Studentʼs t test.) in NLK
phosphorylation at Thr298 during ribosome-insufficiency in
DBA-patient derived iPSCs compared with those with the causal
genetic mutation corrected (Supplementary Fig. 5c).
NLK expression limited in non-erythroid progenitors. As NLK
lacks the TXY motif in the activation loop of other MAPK
members, it has been proposed that NLK is constitutively active
and over expression alone increases cellular activity levels17,43,46.
However upstream signaling regulators increase kinase activity
without modulating expression13–16,18–21. Over expression of
NLK cDNA (without NLK 3′UTR) did not appreciably decrease
CD235+ erythroid differentiation (p= 0.2249 and 0.2474,
respectively) in control or RPS19-insufficiency (Fig. 5a.i). Similar
to erythroid expansion in control cells, over-expressed NLK
cDNA did not impact myeloid expansion (p= 0.0489). Unex-
pectedly, NLK cDNA expression resulted in a dramatic reduction
(p= 0.001) in myeloid expansion (Fig. 5a.ii). P values were
defined by paired Studentʼs t test. Consistent with Fig. 2a/b,
expression of NLK cDNA with an intact 3′UTR mimicked the
endogenous condition with no impact on myeloid expansion
(Fig. 5a.ii). These data are consistent with a model in which NLK
is not constitutively active and is induced during ribosome
insufficiency, but does not explain why NLK without a 3′UTR
impacts myelopoiesis while endogenous or recombinant NLK
with an intact 3′UTR does not.
Compared with erythroblasts, endogenous NLK expression is
significantly reduced in myeloid cells (Fig. 3a–c). NLK
expression is highly sensitive to miRNAs6,22,24,51 that bind to
the NLK 3′untranslated region (3′UTR) leading to transcript
degradation6,24,51 Fitting with the NLK 3′UTR suppressing
NLK expression in non-erythroid progenitors, fusion of the
NLK 3′UTR to the luciferase gene reduced luciferase activity
by ~70% in CD41a+ megakaryocyte and CD11b+ myeloid
populations, compared with luciferase activity in CD235+
erythroid progenitors (Fig. 5b.i). Luciferase activity was not
differentially influenced by the NLK 5′UTR across the different
lineages (Fig. 5b.ii).
Downregulation of NLK by miR-181 binding to the 3′UTR
has been reported previously22,23. Deregulation of miR-181
significantly alters the ratio of lymphoid and myeloid lineages
during differentiation51–55 and is often downregulated in
leukemia51,52,54. For example, the expression of miR-181 in
MEPs determines megakaryocyte versus erythroid commit-
ment55. Consequently, we were precluded from direct inhibi-
tion of miR-181 in differentiating progenitors. However, we
utilized three alternative strategies to determine if miR-181 is
involved in regulating NLK expression.
First, since miR-181 induction is critical for lymphoid
differentiation51,53, we anticipated miR-181 expression would be
high in the LCL line (DR07). MiR-181 was expressed 8.6 times
higher than in CD34+ HSPCs. In contrast, NLK expression was 3.5-
fold lower (Supplementary Fig 6a). We also expressed a miR-181
sponge that sequesters free miR-18156 in LCLs from a healthy
control (DR07), control transduced with shRNA against RPS19
(DR07+ shRPS19), and three DBA patients (DG0005, DG0006,
and DG0079). No significant differences were observed in miR-181
between cell lines with or without miR-181 inhibitor (Supplemen-
tary Fig 6b). In contrast, NLK expression was increased between
3.5- and 4.2-fold in all lines upon miR-181 inhibition (Supplemen-
tary Fig. 6c). Interestingly, miR-181 inhibition did not impact
proliferation in control cells, but reduced proliferation between 46
and 50% in RPS19-insufficient cells (Supplementary Fig. 6d).
Although LCLs do not differentiate and are not of erythroid origin,
these data indicate NLK expression is inversely correlated with
miR-181 and that increasing NLK expression in these cells
sensitizes LCLs to ribosomal insufficiency.
Second, although unable to inhibit miR-181 in HSPCs due to
the multiple NLK-independent roles of this miRNA in hemato-
poiesis, we sought to determine if miR-181 was regulating NLK
expression by mutating the potential miR-181 binding site in the
3′UTR. Expression of miR-181 was between 6.2- and 6.6-fold
higher in non-erythroid cells than erythroblasts but neither
RPS19-insuffiicency nor expression of various NLK constructs
influenced miR-181 expression (Fig. 5c.i).
As observed in Fig. 3b, NLK was expressed 4–5-fold more in
erythroid than non-erythroid cells. Unexpectedly, expression of all
recombinant NLK mutants did not dramatically increase already
high levels of NLK expression in erythroblasts (Fig. 5c.ii). However,
NLK with absent or mutated 3′UTR both increased NLK expression
over threefold in non-erythroid lineages, reaching between 75 and
85% of levels expressed in erythroblasts. Transduction of
recombinant NLK with an intact 3′UTR failed to significantly
increase NLK expression in non-erythroid cells (Fig. 5c.ii).
These data indicate that the miR-181 binding site within the 3′
UTR is required for suppression of NLK in non-erythroid cells, but
the consequences of “forced” NLK expression in non-erythroid cells
was pronounced. In agreement with Fig. 5a, “forced” expression of
NLK in non-erythroid progenitors did not influence lineage
expansion unless NLK could be activated (Fig. 5c.iii). Few
megakaryocytes and <30% of control myeloid populations were
recovered from RPS19-insufficient populations expressing NLK
with no or mutated 3′UTR (Fig. 5c.iii). Erythropoiesis was only
mildly affected by modulation of NLK expression.
Third, the role of the miR181-binding site in the NLK 3′UTR was
confirmed by mutating the site using CRISPR-Cas9 in primary
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human hematopoietic cells. After screening guide RNAs (gRNAs)
that selectively target the potential miR-181 binding site (see
Supplementary Fig. 6e), gRNA, along with Cas9, were electroporated
into control and RPS19-insufficient CD34+ HSPCs. As a control,
gRNA targeting RelA was introduced. Cells were differentiated prior
to counting, sorting and sequencing to determine the percentage of
cells baring mutations in NLK 3′UTR (a schematic of the
experiment is presented in Supplementary Fig. 6f).
Subsequently, CD235+, CD41a+, and CD11b+ numbers were
calculated (Fig. 5d gray bars). After sequencing, the percentage of
cells baring mutations in NLK 3′UTR (Fig. 5e blue bars) and RelA
(Fig. 5e red bars) was determined. In ribosome-competent cells in
excess of 40% of cells were successfully mutated by both NLK 3′
UTR- and RelA-targeting in all three cell lineages. Even with 40%
cells carrying mutations, no reduction in cell population was
observed (Fig. 5d).
A different pattern was observed in RPS19-insufficient progenitor
cells. The percentage of cells with NLK 3′UTR or RelA mutations
was not significantly different from controls (Fig. 5d blue and red
bars) and the mutations do not impact the total cell population
(Fig. 5d gray bars). In RPS19-insufficient CD41a+ megakaryocyte
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reduction in total population in observed in populations with NLK
3′UTR mutations introduced and less than 8% of these populations
carried NLK 3′UTR mutations (Fig. 5d blue bars). This indicates
that RPS19-insufficient cells with the mutation were unable to
expand (Fig. 5d red bars). As observed in Fig. 4c, mutation of the
NLK 3′UTR had no impact on already highly sensitive erythroid
differentiation. However CD41a+ megakaryocyte and CD11b+
myeloid populations were 80.4% and 75.1%, respectively, more
sensitive to RPS19-insufficiency (Fig. 5e). These data demonstrate
that miR-181 suppression of NLK expression protects non-erythroid
progenitors from lineage expansion defects resulting from ribosomal
insufficiency-induced activation of NLK (see Fig. 5f).
NLK activation is dependent on p53 activation. Ribosome-
insufficiency induces stabilization of p53 protein and contributes
to DBA pathogenesis27,57–59. We transduced shRNA against p53
and RPS19 in differentiating HSPCs and observed a greatly
reduced activation of NLK compared with RPS19-insufficient
cultures without shRNA against p53 (Fig. 6a.i–iii). To further
examine the role of p53 in NLK activation in our model and DBA
patient samples, we utilized Nutlin-3. Nutlin-3 inhibits the E3
ubiquitin ligase MDM2 binding of p53 and subsequently stabi-
lizes p53 from ubiquitin-dependent degradation59. NLK dimeri-
zes upon activation46 and the detection of FRET from dimerized
YFP- and CFP-NLK pairs correlates with NLK activity in RPS19-
insufficiency (Fig. 3d). Nutlin-3 increased FRET signaling from
9.0% (Fig. 6b.i) to 50.2% (Fig. 6b.ii) of the population. We gated
p53 expression into p53low in which 6.6% of cells activate NLK,
and p53hi where 91.9% of cells activate NLK (Fig. 6b.ii). RPS19-
insufficiency increased the p53hi population from 8.1 to 34.1%,
corresponding to an increase from 9.0 to 36.1% of cells with
elevated NLK-dimerization (Fig. 6b.iii).
Next we compared healthy mononuclear bone marrow cells
stimulated with (i) vehicle control, (ii) Nutlin-3, (iii) or to a DBA
sample pooled from three patients (Fig. 6c). Nutlin-3 again
increased the percentage of p53hi cells (from 6.6% to 31.7%),
corresponding to an increase of 9.4% to 30.1% of cells with
dimerizing NLK (Fig. 6c.ii). Compared with controls, DBA samples
demonstrated a modestly higher percentage of cells with elevated
p53 levels (6.6–12.8%) which correlated with higher (9.4–14.4%)
NLK dimerization (Fig. 6c.iii). NLK in vitro kinase assay was
performed and confirmed a correlation between NLK dimerization
and activity (Supplementary Fig. 7a). Comparison of values between
kinase assay and flow cytometry values are tabulated in Fig. 6d.
In Kp53A1 cells, robust activation of NLK was observed
at temperatures supporting p53 activation (Supplementary
Fig. 3b–e). Taken together, these data demonstrate that activation
of NLK is p53-dependent.
RPS19-insufficiency increases NLK activation in MEPs. NLK is
transiently and modestly activated in normal erythropoiesis but
becomes chronically activated in ribosomal insufficiency (Fig. 4a).
NLK is activated in CD71+ and CD235+ erythroblasts (Figs. 3–6)
but we sought to determine the stage of differentiation NLK was
activated in ribosome insufficiency. As reported60, Lin-Kit+
progenitors from RPL11+/+ and RPL11+/flox mice were sorted
into Sca+ HSC and non-committed progenitor populations while
Sca− cells were further sorted into CD34-CD16/32− MEPs,
CD34+CD16/32+ Granulocyte/Macrophage Progenitors (GMPs)
and CD34+CD16/32− Common Myeloid Progenitors (CMPs).
Low NLK activity was observed in Lin−Kit+Sca+ and CMP
populations from both control and RPL11−insufficient mice. A
mild increase in NLK activity was observed in RPL11+/+ MEP
and GMP populations. A 6.3-fold increase in NLK activity was
observed comparing MEPs from ribosome-insufficient mice to
controls (Fig. 6e) while no NLK activity was observed in GMPs
from either group.
We also sorted transduced human CB progenitors into four
distinct progenitor populations after 7 days of differentiation
(Supplementary Fig. 7b)61. Non-erythroid progenitor population
(CD71−CD235−), a population enriched for MEPs and BFU-Es
(CD71lowCD235−), a population enriched for CFU-Es (CD71+
CD235−), and a population enriched in pro-erythroblasts
and intermediate erythroblasts (CD71+CD235+). Ribosome-
insufficiency does not induce NLK activation in non-erythroid
progenitors but NLK activity is over 6-fold above control in all
three erythroid progenitor and precursor populations (Fig. 6f).
Effects of NLK phosphorylation of c-Myb and Raptor. NLK has
many reported downstream effectors, including transcription fac-
tors involved in erythropoiesis16,18,21,62, with the potential to
impact DBA pathogenesis. While this study is not designed to
determine all factors downstream of NLK contributing to the DBA
phenotype, we have determined that both Raptor and c-Myb serve
as substrates in vitro (Figs. 3–6) and wanted to determine if they are
phosphorylated by NLK in ribosome-insufficiency. In osmotic
stress, NLK phosphorylates Raptor at Ser86316. Control and RPS19-
insufficient progenitors derived from transduced CD34+ HSPCs
were differentiated for 10 days and sorted into CD71+ and CD71–
populations, prior to being assessed for Raptor phosphorylation at
Ser863 by Western blot analysis. As with NLK activation (Fig. 3c),
phosphorylation was primarily restricted to RPS19-insufficiency in
CD71+ erythroblasts (Fig. 7a). Raptor expression was equivalent
across samples (Fig. 7a) and NLK, pThr298-NLK, and GAPDH
expression are documented in Fig. 3c.
Raptor phosphorylation can influence mTOR activity by
preventing mTOR-associated Raptor from localizing to the
Fig. 5 Upregulation of miR181 suppresses NLK expression in non-erythroid progenitors and protects cells from RPS19-insufficiency. a Wild type NLK
cDNA was generated with or without the NLK 3′UTR. Cord blood CD34+HSPCs were transduced with NLK construct and siRNA and differentiated for
12 days. Erythroid (i—red) and Myeloid (ii—purple) expansion was calculated by multiplying viable cell counts by % CD235+ or CD11b+, respectively.
Results are displayed as a percentage of cells of each lineage relative to untreated controls. b—green CD34+ progenitors were transduced with shRNA
against a non-targeting sequence (NT) or RPS19 (shRPS19) and the NLK minimal promoter upstream of the luciferase gene (i) or luciferase gene with the
NLK 3’UTR downstream (ii). After 12 days of differentiation in erythroid media, cultures were sorted into designated hematopoietic lineages and luciferase
activity was assessed. c CD34+ progenitors were transduced with shLuc (white bars) or shRPS19 (dark bars). In addition, vectors expressing cDNA for NLK
with either a 3′UTR with 3 stop sequences (NLK stop), the wild type NLK 3′UTR (NLKWT 3’UTR) or 3′UTR with the miR181 binding site mutated (NLK Mut
3′UTR). After differentiation, cells were sorted into hematopoietic lineage and assessed for miR181 expression (i) or NLK expression (iii) by qRT-PCR. The
relative number of each hematopoietic lineage was determined as a percentage of the number observed in controls expressing only endogenous NLK (iii).
d After counting and sorting for lineage (gray bars), cells were sequenced to determine the percentage of cells within each population carrying indels in
miR181 binding site (blue) and RelA (red). e The percentage of cells carrying indels in NLK 3′UTR miR181 binding site (blue) and RelA (red) in each
treatment were further compared for impact on population expansion between lineages. f A diagrammatic representation of the induction of miR-181 in
non-erythroid progenitors leads to binding to the NLK 3′UTR to facilitate degradation of the NLK transcript. Bars represent means ± SD with individual data
points overlaid. n= 3 independent experiments performed in triplicate. Statistics: two-tailed Student’s t test, significant *p < 0.05.Also see Supplementary
Fig. 6. Source data are provided as a Source Data file.
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lysosomal membrane16. Strong co-localization (depicted in
yellow) of Raptor (red) with the lysosome (green) was observed
by fluorescence confocal microscopy in CD71+CD235− differ-
entiating progenitors in control cells (shLuc) expressing non-
targeting or siRNA against NLK (Fig. 7b). Co-localization was
disrupted in RPS19-insufficiency but restored when NLK was
silenced (Fig. 7b), indicating NLK-dependent phosphorylation
and mis-localization of Raptor in RPS19-insufficiency.
NLK-dependent phosphorylation of c-Myb in breast cancer
and Wnt signaling has been demonstrated to facilitate rapid
ubiquitination and subsequent proteasome degradation4,14,15,24.
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Fig. 6 NLK is activated in early erythroid progenitors and requires P53 stabilization in RPS19-insufficiency. a Cord blood CD34+ progenitors were
transduced with lentivirus expressing shRNA against luciferase (shLuc) or RPS19 (shRPS19) co-expressing GFP. Cells were also transduced with or without
shRNA against p53 co-expressing mCherry. After 36 h, GFP+ and GFP+,mCherry+ cells were differentiated in erythroid media for 8 days, followed by NLK
kinase assay (i—NLK: orange, ii—Myb: blue, iii—Raptor: green) and qRT-PCR analysis of RPS19 (iv) and p53 (v) expression. b CD34+ cord blood HSPCs
were transduced with control shRNA (shLuc) along with YFP- and CFP-tagged NLK and allowed to differentiate for 3 days, in the presence (i) or absence
(ii) of Nutlin-3. Cells were stained for p53 and both p53 and FRET was measured by flow cytometry. For comparison, HSPCs were transduced with shRNA
against RPS19 (iii). c Bone marrow mononuclear cells from healthy donors were transduced with YFP- and CFP-NLK and incubated alone (i), or with Nutlin-
3 (ii) for 24 h, prior to p53 and FRET analysis. Bone marrow mononuclear cells from three DBA patients were pooled and analyzed simultaneously (iii).
d Documentation of the percentage of cells with dimerizing NLK in p53hi and p53low is tabulated and can be compared with NLK in vitro kinase
activity. e—green Samples were gated to include non-erythroid CD71-CD235- populations, MEP- and BFU-E-enriched CD71lowCD235- populations, CFU-E-
enriched CD71hiCD235- populations and proerythroblast and intermediate erythroblast CD71hiCD235+ populations. Sorted populations were lysed and
immunoprecipitated NLK was subjected to in vitro kinase assay examining Raptor phosphorylation as a substrate. Activity was normalized to the non-
erythroid control samples. f—green Sorted populations were lysed and immunoprecipitated NLK was subjected to in vitro kinase assay examining Raptor
phosphorylation as a substrate. Activity was normalized to the Lin-Kit+Sca+ RPL11+/+ samples. Bars represent means ± SD with individual data points
overlaid. n= 3 independent experiments performed in triplicate. Statistics: two-tailed Student’s t test, significant *p < 0.05.Also see Supplementary Fig. 7.
Source data are provided as a Source Data file.
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reduced by over 80% in RPS19-insufficient erythroid progenitors
relative to controls, when differentiated in vitro. Expression of
siRNA against NLK prevents c-Myb degradation in RPS19-
insufficiency (Fig. 7c). Quantitative RT-PCR revealed c-Myb
mRNA in RPS19-insufficiency was only mildly downregulated
(13% reduction) compared with controls (Fig. 7c) which would be
anticipated if c-Myb was being degraded after NLK-mediated
phosphorylation. Myb serves a number of cellular roles in
erythropoiesis, including transcriptional upregulation of KLF1
and LMO264. In controls we observed inductions of 1.8-fold and
2.4-fold of LMO2 and KLF1, respectively, but RPS19-insufficient
cultures displayed only 1.3- and 1.8-fold inductions. Upon
silencing of NLK, LMO2, and KLF1 induction was restored to
1.6-fold and 2.3-fold, respectively (Supplementary Fig. 7c).
We sought to determine if NLK-mediated phosphorylation was
responsible for proteasomal degradation during RPS19-insuffi-
ciency, Kp53A1 cells cultured at 32 °C activate p53 and NLK
(Supplementary Fig. 3b–e), c-Myb protein is reduced and silencing
of NLK prevents c-Myb loss (Supplementary Fig. 7d). C-Myb is
undetectable after 48 h of NLK activation so we examined c-Myb
expression and phosphorylation at 0, 16, and 48 h after
stimulation. To determine if the lysosome or proteasome were
involved in the degradation of c-Myb, we also treated cells with
chloroquine or lactacystin. Despite a reduction in c-Myb
expression, c-Myb phosphorylation was readily detectable after
16 h of NLK activity (Fig. 7d). Expression and phosphorylation of
c-Myb was not influenced by chloroquine but both were sustained
out to 48 h with lactacystin treatment (Fig. 7d). Our data indicate
both Raptor and c-Myb are phosphorylated downstream of NLK
activation in RPS19-insufficiency.
Chemical inhibition of NLK enhances erythropoiesis in DBA.
For direct comparison of the effects of SD208 on NLK activity
and erythropoiesis between murine and human DBA models, we
isolated CD34+ (human) and Lin−Kit+ (murine) HSPCs from
control and disease states and differentiated them in the presence































































































Fig. 7 NLK phosphorylation of c-Myb results in ubiquitination and proteasome degradation. a CD34+ CB HSPCs transduced with shRNA against control
(shLuc) or RPS19 (shRPS19) were differentiated for 10 days and sorted into CD71+ and CD71– fractions. Three independent experiments were pooled and
populations were probed by Western blot analysis examining phospho-Ser863-Raptor and total Raptor. This experiment was performed in conjunction with
Fig. 3c. b Cord blood CD34+ progenitors were transduced with shRNA against luciferase (shLuc) or RPS19 (shRPS19) and siRNA against NLK (siNLK) or a
non-targeting (NT) sequence and differentiated for 8 days. Cells were fixed, permeablized and incubated with Cy3-labeled antibody against Raptor
(pseudo-colored red) and lysosomes were visualized by incubation with FITC-labeled antibody recognizing LAMP1 (pseudo-colored green). Areas of co-
localization (merge) are indicated in yellow and yellow dotted boxes are magnified in inserts to the far right. Scale bar, 15 µm c Fetal liver CD34+
progenitors were transduced with shRNA against luciferase (shLuc) or RPS19 (shRPS19) in conjunction with siRNA against NLK (siNLK) or a non-targeting
sequence (NT). Cells were differentiated for 5 days and split into two aliquots. One aliquot was lysed and probed for c-Myb protein expression by Western
blot, while the second aliquot was subjected to qRT-PCR to examine c-Myb mRNA expression. d Kp53A1 cells were treated with vehicle alone, lactacystin
or chloroquine for 30min, prior to switching cells from 37 to 32 °C for the indicated times. Cells were lysed, normalized for protein and split into two.
C-Myb was immunoprecipitated from one sample before Western blot analysis for phosphorylated serine, while the other sample was subjected to
Western blot for c-Myb and GAPDH. Bars represent means ± SD with individual data points overlaid. n= 3 independent experiments performed in
triplicate. Also see Supplementary Fig. 7. Source data are provided as a Source Data file.
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SD208 did not significantly impact erythroid expansion of
human HSPCs transduced with control shRNA (100% to ~105%),
however SD208 increased erythroid expansion in both RPS19-
and RPL11-insufficiency from 8.7% to 38.7% (p= 0.0056) and
5.8% to 36.7% (p= 0.0135) of control, respectively (Fig. 8a).
In mice, Lin−Kit+ cells from three mice expressing a tetracycline-
inducible shRNA against RPS19 were differentiated for 8 days in the
absence or presence of doxycycline and/or SD208. RPS19-
insufficiency reduced Ter119+ erythroblasts to 24.3, 20.3, and
18.5% of controls differentiated in the absence of doxycycline. The
presence of SD208 with doxycycline improved erythropoiesis to
83.2, 81.1, and 76.6% of controls (p= 0.0011) (Fig. 8b).
Three mature RPL11+/lox mice were treated with tamoxifen for
eight weeks to induce heterozygous deletion of RPL11. As
controls, three different RPL11+/+ littermates of the same mouse
strain were treated with tamoxifen. Lin−Kit+ HSPCs were
isolated and differentiated in the presence or absence of SD208
for 8 days. As observed in other DBA models, RPL11-
insufficiency reduced erythropoiesis but SD208 improved ery-
thropoiesis from 31.2% to 57.3%, 26.4% to 56.8% and 18.6% to
50.3% of controls (p= 0.0059) (Fig. 8b).
NLK phosphorylation at Thr298 was elevated in RPS19-
insufficient differentiating human erythroblasts 2.5-fold above
controls using conventional Western blot analysis (Fig. 3c).
Capillary electrophoresis using the Peggy-Sue™ platform (Protein
Simple©), revealed a similar 2.3-fold increase in NLK phosphoryla-
tion at Thr298 in RPS19-insufficiency, while RPL11-insufficiency
revealed a 1.96-fold increase (Fig. 8c). SD208 reduced NLK activity
from 2.3-fold to 1.3-fold (p= 0.025) above controls in RPS19-
insufficiency and 1.96-fold to 1.2-fold (p= 0.0431) in RPL11-
insufficiency. Parallel results were obtained by analysis of in vitro
NLK activity (Supplementary Fig. 8a).
In HPSCs from DBA mouse models, detection of NLK Thr298
phosphorylation by capillary electrophoresis increased 3.1-fold
and 2.5-fold over controls in RPS19- and RPL11-insufficiency
respectively. SD208 reduced this to 1.3-fold (p= 0.0027) and 1.3-
fold (p= 0.0393) of controls (Fig. 8d) and correlated with in vitro
NLK activity (Supplementary Fig. 8b).
Increased erythropoiesis in SD208-treated DBA BM MNCs.
HSPCs isolated from three DBA patients or healthy controls were
cultured in the presence or absence of 5 µM SD208. In the
absence of SD208, differentiation of CD235+ erythroblasts from
DBA patient HSPCs was reduced to 23.0, 11.6, and 8.4% of
healthy controls. The presence of SD208 increased this to 43.7,
24.7, and 19.4% (p= 0.1806) (Fig. 8e). This correlates to a mean
increase of 2.11-fold. Capillary electrophoresis revealed a 1.68-
fold (p= 0.0487) increase in NLK phosphorylation at Thr298 in
DBA patient samples relative to healthy controls (Fig. 8f). SD208
reduced phosphorylation to 1.11-fold (p= 0.0253) of controls.
Corresponding decreases were observed in immunopurified NLK
(Supplementary Fig. 8c). All P values were defined by paired
Studentʼs t test. Collectively, SD208 reduced NLK activity and
improved erythropoiesis in all models examined, indicating that
targeting NLK activation with small molecules has the potential
of improving erythropoiesis in DBA patients.
Discussion
Advances in DBA therapy have greatly improved life expectancy
and outcomes1,57,65. Stem cell transplantation can cure the
hematological manifestations of the disease, but is associated with
a significant risk of life threatening complications such as graft
versus host disease1,57. Iron overload and other complications are
associated with chronic red blood cell transfusions1,57. New
targets and therapies are needed to improve patient outcome and
quality of life.
Kinases, are highly druggable targets66. DBA is a genetic dis-
ease, but causal mutations can exist within one of at least 22
genes, so identification of aberrantly regulated kinases common
to all genetic variants offers particular promise. Our study
documents sustained activation of NLK in human and murine
models of DBA with mutations in different ribosomal subunits
and chemical inhibition of NLK improved erythropoiesis in all of
the models examined.
Systemic inhibition of NLK will not only suppress NLK in
erythroid progenitors, but also every other cell type exposed to it.
We demonstrated NLK is minimally expressed in non-erythroid
hematopoietic lineages and SD208 treatment did not impact
differentiation in these lineages in either control or ribosome-
insufficient cells. Beyond hematopoietic cells, NLK is modestly
expressed in most tissues with highest expression in the brain6.
NLK knockout mice that are born display smaller size, pulmon-
ary67 and some neurological defects68. Therefore, systemic inhi-
bition of NLK may have adverse effects, particularly in the
vascular and nervous systems. Aberrant stromal development in
the bone marrow was also observed in NLK null mice68, which
could impact erythropoiesis in DBA patients.
Despite differences in mechanisms regulating erythroid pro-
duction in humans and mice, DBA-like phenotypes are observed
in both species in response to ribosomal insufficiency49,50, sug-
gesting a conserved molecular mechanism. Although our data
demonstrate that small molecules are capable of inhibiting NLK
activity, these compounds are not yet ready for clinical applica-
tion. Our observation that NLK activation is conserved and
contributes to erythroid defects highlights the relevance of using
these model systems to study DBA and develop novel approaches
to target NLK in the future.
Methods
Cell culture. Primary human CD34+ hematopoietic stem and progenitor cells were
purified from cord or peripheral blood (New York Blood Center) or from human fetal
liver tissue (Advanced Bioscience Resources and University of California, Los Angeles
Center for AIDS Research) by using magnetic-activated cell sorting (Miltenyi Biotec)
and were cryopreserved. Upon thawing, cells were cultured in x-Vivo15 media
(Lonza) containing 10% fetal bovine serum, fms-related tyrosine kinase 3 (50 ng/ml),
thyroid peroxidase (50 ng/ml), interleukin-3 (IL-3; 20 ng/ml), interleukin-6 (IL-6;
20 ng/ml), and stem cell factor (50 ng/ml). When applied, TGFβ1 was added at 5 ng/
ml. Kp53A1 cells were obtained from Javier Leon and cultured in DMEM supple-
mented with 10% fetal bovine serum at 37 or 32 °C. Stable cell lines expressing shRNA
against RPS19 with differing efficiencies; shRPS19#8 (high), shRPS19#1 (moderate),
and shRPS19#3 (low) were generated by co-transfecting shRNA-carrying vectors
(pLVTH) with neomycin-carrying vector (pcDNA3.1) using Lipofectamine® 2000
(Thermo Fisher). Individual clones were harvested and expanded in 100 µg/ml neo-
mycin and RPS19 expression examined by Western blot and qRT-PCR. CD34+
progenitors were obtained from mononuclear bone marrow DBA patient samples
using magnetic-activated cell sorting (Miltenyi Biotec) and differentiated for 12 days.
Patient samples were obtained and provided by Dr. Hanna Gazda and their collection
and use was approved by the institutional review board at Boston Children’s Hospital.
Informed consent was obtained from affected individuals and their family members
participating in the study.
Lentiviral transduction. Primary CD34+ cells were transduced using spinoculation
(30min at 800 g) at MOI 50 with lentivirus expressing shRNA against RPS19,
RPL11, p53, NLK, or luciferase (Luc), siRNA against NLK or a non-targeting
sequence, or cDNA expressing NLK with wild type 3′UTR, a mutated 3′UTR or no
3′UTR or “escape” NLK. YFP- or CFP- tags were inserted 3′ of NLK using
restriction enzyme digestion and ligation. Kinase-deficient NLK was generated by
introducing the K115M mutation using point mutagenesis as reported previously21.
Virus co-expressed GFP, RFP, mCherry, or puromycin to enable selection.
Compounds. Small molecule inhibitors were purchased from SelleckChem, with
the exception of SD208 (Tocris), ITD-1 (Adooq Bioscience), and were diluted in
dimethylsulfoxide (DMSO). Inhibitors were added to cells at indicated con-
centrations with a final DMSO concentration of 0.5%. Lactacystin and chloroquine
were purchased from Sigma Aldrich and diluted according to manufacturer’s
instructions, and added to cells at a concentration of 1 μM, 10 μM and 30 μM,
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Fig. 8 NLK inhibition increases expansion of erythroid progenitors from human and murine models of DBA. a Human cord blood CD34+ progenitors
were transduced with lentivirus co-expressing GFP with shRNA against luciferase (shLuc), RPS19 (shRPS19), or RPL11 (shRPL11). After 36 h GFP+ cells were
differentiated in erythroid media in the presence or absence of 5 µM SD208 for 15 days. Cells were counted and assessed for cell surface expression of
CD235. b Lin-Kit+ hematopoietic progenitors were obtained from three mouse embryos expressing tetracycline-inducible shRNA against RPS19 at day
E14.5 or three untreated mice, and thee mature RPL11+/+ or three mature RPL11+/lox mice treated with tamoxifen for eight weeks. Cells were grown in the
presence or absence of doxycycline and/or SD208 for 8 days prior to counting and assessing for Ter119 surface expression. Values were expressed as a
percentage relative to untreated controls. c, d Intracellular phosphorylation of NLK at Thr298 was determined by capillary electrophoresis using the Peggy
Sue™ Automated Western blotting platform. After lysis, 4 µg of protein from the CD235+ population was probed against pThr298-NLK and normalized to
GAPDH. Detected NLK phosphorylation is plotted relative to untreated control. e CD34+ HSPCs were isolated from three healthy control and three DBA
patient mononuclear bone marrow aspirates by magnetic bead sorting and differentiated in the presence or absence of SD208 for 14 days. After counting
the total cell population, the ratio of CD235+ erythroblasts was determined by flow cytometry and number of CD235+ erythroblasts calculated. This was
expressed as a percentage of the average number of erythroid cells present in untreated healthy controls. f NLK phosphorylation was assessed by capillary
electrophoresis as above. Bars represent means ± SD with individual data points overlaid. Purple depicts untreated controls, yellow depicts controls treated
with SD208, red depicts untreated DBA progenitors, while blue depicts DBA progenitors treated with SD208. n= 3 independent experiments performed in
triplicate. Statistics: two-tailed Student’s t test, significant *p < 0.05. Also see Supplementary Fig. 8. Source data are provided as a Source Data file.
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respectively. IC50 calculations were obtained using 8–9 concentrations of com-
pound and generated using the IC50 Calculator software by AAT Bioquest®. NLK,
p38, or ALK5 for in vitro kinase assays were immunopurified from Kp53A1 cells.
NLK activation was induced by incubating cells at 32° for 24-48 h, p38 by sti-
mulating with IL-3, IL-6, SCF, and Epo at the same concentrations used for dif-
ferentiating erythroid progenitors. IC50 values for each kinase and compound were
plotted along a horizontal bar with our observed value superimposed next to
documented values (if available). IC50 values were obtained for each kinase against
each substrate (e.g., NLK phosphorylation of NLK, c-Myb, and Raptor), but as
IC50 curves were virtually identical for each substrate, only one is presented.
Colony assays. Sorted hematopoietic cells were seeded in methylcellulose medium
containing IL-3, stem cell factor, granulocyte macrophage–colony-stimulating
factor, and erythropoietin (H4434; STEMCELL Technologies) in triplicate, with
1000 cells per plate. Erythroid (burst-forming unit erythroid) and myeloid (colony-
forming unit, granulocyte-macrophage) colonies were counted 14–18 days later. In
some cases, 3000 (shRPL11) or 5000 (shRPS19+ TGFβ) cells per plate were added
to ensure enough colonies for robust statistical analysis.
Flow cytometry. For cell surface flow cytometry, cells were incubated with human
Fc receptor binding inhibitor (#14-9161−73; eBioscience) followed by primary
antibodies CD235−APC (#306607; BioLegend) CD41-FITC (#303703; BioLegend)
and CD11b-PE/Cy5 (#101209; BioLegend) or CD-71-APC (BD551374; BD Bios-
ciences), p53-PECy7 (NB200-171; Novus), Sca-1-PE (#12-5981-81; eBioscience),
CD34-Fluor®450 (#48-0341-82; eBioscience) and CD16/32-FITC (#101305; Bio-
Legend). FRET measurements were obtained as described69. To measure ECFP and
FRET cells were excited with the 405 nm laser and fluorescence was collected in the
ECFP channel with a standard 450/40 filter, while the FRET-signal was measured
with a 529/24 filter. To measure EYFP, cells were excited with the 488 nm laser
while emission was also taken with a 529/24 filter. Data were collected on a DxP10
flow cytometer (Cytek) and analyzed by using FlowJo Software, v.9.7.2.
Kinase and ubiquitination assays. For NLK kinase analysis, cultures were treated
as indicated and lysed for 30 min at 4 °C in 750 μl of kinase lysis buffer (50 mM
Tris [pH 7.4], 5 mM EDTA, 250 mM NaCl, 0.1% Triton X-100, 50 mM NaF, 0.1
trypsin inhibitor unit of aprotinin per ml, 50 μg of phenylmethylsulfonyl fluoride
per ml, 100 μM sodium vanadate, 1 μg of leupeptin per ml). For TGFβR1 kinase
analysis, cells were lysed in membrane kinase buffer (10 mM Tris-HCl (pH8.0),
140 mM NaCl, 300 mM KCl, 0.5% Triton X-100, and 0.5% sodium deoxycholate
with complete protease inhibitor cocktail (Roche)). Extracts were clarified, and
equivalent protein was incubated overnight at 4 °C with antibody (NLK: #AB97642;
Abcam, TGFβR1: V22; Santa Cruz Biotechnology). Immune complexes were col-
lected with Catch and Release® V2.0 Reversible Immunoprecipitation System and
diluted in kinase buffer (25 mM Tris [pH 7.4], 10 mMMgCl2, 1 mM dithiothreitol).
When cell numbers were limiting, NLK activity was amplified by adding 0.5 µg
dephosphorylated NLK prior to performing kinase reaction. 50 μl of kinase buffer
containing NLK or TGFβR1 sample and 5 μM ATP was incubated in the presence
of biotinylated substrate (NLK, c-Myb, or Raptor for NLK and Smad2 or Smad3 for
TGFβR1) immobilized on streptavidin-coated 96-well plates. The kinase reaction
was allowed to proceed for 30 min at 37 °C before kinase was removed. After
vigorous washing in kinase buffer, substrates were incubated for 60 min with
antibody against phospho-Serine/Threonine (#525280; Calbiochem), and detected
by HRP-conjugated anti-mouse antibody (#170-6516; BioRad) or a combination of
phospho-Serine-HRP (ab9334; abcam) and phospho-Threonine-HRP (sc-5267;
Santa Cruz Biotechnology) and SuperSignal® West Pico Chemiluminescent Sub-
strate (Thermo Scientific). Signal was detected at 428 nm by Synergy™ H1 hybrid
multi-mode microplate reader (BioTek®). Prior to kinase analysis, NLK c-Myb,
Raptor, Smad2, and Smad3 were immunopurified by Catch and Release® V2.0
Reversible Immunoprecipitation System and biotinylated as per manufacturer’s
instructions (EZ Link™ NHS Biotin; Thermo Scientific) and immobilized on
Pierce® NeutrAvidin-coated 96-well plates (Thermo Scientific). Background
phosphorylation was removed by 30 min incubation in the presence of 0.1 unit/ml
calf intestinal phosphatase (New England Biolabs). Ubiquitination assays were
performed as above, except cells lysates were applied directly to plates in the
presence of lactacystin for 2 h prior to incubation with anti-ubiquitin antibody
(#P4D1; Santa Cruz Biotechnology).
qRT-PCR. RNA was extracted by using total RNA mini kit (Bio-Rad). RNA was
transcribed into cDNA by using the iScript cDNA Synthesis Kit (Bio-Rad). The
quantitative RT-PCR (qRT-PCR) reaction was run with iQ SYBR Green MasterMix
(Bio-Rad) using the CFX384 Touch Real-Time PCR Detection System (Bio-Rad).
7SL small cytoplasmic RNA27 was used as an internal control. miRNA was
quantified using TaqMan® Small RNA Assays (Applied Biosystems) as per man-
ufacturer’s directions and normalized to snoRNA. Fold change of mRNA and
miRNA was calculated by using the comparative Ct method. List of primers is
provided in Supplementary Table 1.
Luciferase assay. The NLK minimal promoter (1019 5′ nucleotides) and NLK
3′UTR (1885 3′ nucleotides) were cloned upstream, or downstream respectively,
of firefly luciferase in pLenti-GIII-CMV-RFP-2A-Puro (abm). Transduced into
CD34+ cord blood progenitors were differentiated in 1 µg/ml puromycin for
6 days. Transduction efficiency was normalized by RFP expression and firefly
luciferase activity determined by Luciferase Assay Reagent II from Dual-Lucifer-
ase® Reporter (DLR™) Assay System (Promega). Luminescence was assessed using a
Synergy™ H1 hybrid multi-mode microplate reader (BioTek®).
Immunoprecipitation and blotting. Antibodies against RPS19 (#AB40833; Abcam;
1:200 dilution), NLK (#AB97642; Abcam; 1:1000 dilution, #PAS-21877; Invitrogen;
1:1000, #PAS-25953; Invitrogen; 1:1000, #94350; Cell Signaling; 1:1000, #3535; Cell
Signaling; 1:500), phosphoThr298-NLK (orb157946; biorbyt; 1:350 dilution), c-Myb
(#12319; Cell Signaling; 1;1000 dilution), Raptor (#AB26264; Abcam 1;1000 dilu-
tion), phospho-Ser863 Raptor (#PAS-64849; ThermoFisher Scientific; 1:500),
phospho-Ser792 Raptor (#2083; Cell Signaling; 1:500), phospho-Serine (#525280;
Calbiochem; 1:1000 dilution), TAK1 (ab109526; abcam; 1:1000), pERK, pJNK, pp38
(#9910; Cell Signaling; 1:1000), ERK (orb160959; biorybt; 1:1000), JNK (#9252; Cell
Signaling; 1:1000), p38 (#8690; Cell Signaling; 1:1000), cdc2/CDK1 (#77055; Cell
Signaling; 1:1000), and CDK2 (#2546; Cell Signaling; 1:1000), and GAPDH
(#MAB374; Millipore; 1:10000) were used according to manufacturer’s instructions.
The target proteins were analyzed by using SuperSignal® West Pico Chemilumi-
nescent Substrate for horseradish peroxidase (Thermo Scientific). Densitometry was
performed using Image J software (http://rsb.info.nih.gov/ij/). When indicated,
proteins were co-immunoprecipitated prior to immunoblotting. Cell lysates were
normalized for protein before preclearing with Protein A/G Agarose (Upstate) for
30 min, before incubating with indicated antibody overnight. Immune complexes
were precipitated with Protein A/G Agarose and separated by SDS-PAGE, before
being subjected to immunoblotting. Molecular size relative to size markers of bands
corresponding with the protein of interest accompanies each blot. Uncropped and
unprocessed scans of blots are provided in the Source Data file.
Capillary electrophoresis. 4 µg of protein was lysed in RIPA lysis buffer and
subjected to capillary electrophoresis using the Peggy-Sue™ platform (Pro-
teinSimple©) as per manufacturer’s instructions. Antibody raised against phospho-
Thr298 NLK (biorbyt) was used at 1:50.
Mice. The RPS19-deficient mouse model contains a doxycycline-regulatable Rps19-
targeting shRNA (shRNA-D) located downstream of the collagen A1 locus, allowing
dose-dependent downregulation of Rps19 expression57. Mice were maintained at the
Lund University animal facility (Sweden) and all animal experiments were performed
with consent from the Lund University animal ethics committee.
Inducible RPL11 heterozygous deletion mice50 were fed a standard chow diet ad
libitum. When indicated, standard chow diet was replaced by tamoxifen diet
(Teklad, Harlan Laboratories) to induce activation of the CreERT2 transgene. All
animals were maintained at the Spanish National Cancer Research Centre (CNIO)
under specific pathogen-free conditions, in agreement with the recommendations
of the Federation of European Laboratory Animal Science Association (FELASA).
All animal procedures were evaluated and approved by the Ethical Committee of
the Carlos III Health Institute, Madrid, Spain (#54-2013-v2).
Cloning and CRISPR/Cas9. Generation of lentiviral constructs expressing NLK
cDNA, NLK cDNA with various 3′UTR mutants, and NLK with an alternative
nucleotide sequence at the siRNA targeting site (escape NLK), as well as luciferase
gene fused to the NLK 5′ or 3′UTR, were generated with standard molecular biology
techniques. For CRISPR–Cas9 disruption of the miR181-binding sequence within the
NLK 3′UTR, a series of sgRNAs were purchased from Synthego and screened for
the ability to disrupt miR181 binding. K562 cells stably expressing luciferase fused to
the NLK 3′UTR were electroporated with sgRNAs and Cas9. Cells were differentiated
towards erythroid or myeloid lineages with hemin or TCA respectively. After 36 h,
luciferase activity was assessed. Control TPA-treated cells induce miR181 and have
reduced luciferase activity so maintained elevated luciferase in TPA treated group
indicates miR181-binding site disruption. A control sgRNA, a poor NLK-targeting
sgRNA and an efficient NLK-targeting sgRNA were electroporated with Cas9 into
CD34+ progenitors and transduced with shRNA against RPS19 and luciferase. After
15 days differentiation populations were counted and assessed by flow cytometry for
expression of CD235, CD41a and CD11b. The indel frequency of each sorted
population was determined after DNA sequencing. Designing primers and analyzing
indel frequency was performed using SnapGene® Schematic and K562 screening data
is presented in Supplementary Fig. 6e.
Statistics. P values for statistical significance were obtained by using a paired
Student t test. Significance was designated as p < 0.05. The data are representative
of at least three independent experiments.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
The data underlying all figures are provided as a Source Data file. The authors declare
that all data supporting the findings of this study are available within the paper (and its
supplementary information files). Details are available from the corresponding author
upon reasonable request.
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